1679 related articles for article (PubMed ID: 17156133)
1. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
2. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
[TBL] [Abstract][Full Text] [Related]
3. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
4. Proteolytic processing of the Alzheimer's disease amyloid precursor protein in brain and platelets.
Evin G; Zhu A; Holsinger RM; Masters CL; Li QX
J Neurosci Res; 2003 Nov; 74(3):386-92. PubMed ID: 14598315
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
Rakover I; Arbel M; Solomon B
Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
[TBL] [Abstract][Full Text] [Related]
8. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice.
Asai M; Hattori C; Iwata N; Saido TC; Sasagawa N; Szabó B; Hashimoto Y; Maruyama K; Tanuma S; Kiso Y; Ishiura S
J Neurochem; 2006 Jan; 96(2):533-40. PubMed ID: 16336629
[TBL] [Abstract][Full Text] [Related]
9. Targeting BACE with small inhibitory nucleic acids - a future for Alzheimer's disease therapy?
Nawrot B
Acta Biochim Pol; 2004; 51(2):431-44. PubMed ID: 15218540
[TBL] [Abstract][Full Text] [Related]
10. Promising multifunctional anti-Alzheimer's dimer bis(7)-Cognitin acting as an activator of protein kinase C regulates activities of alpha-secretase and BACE-1 concurrently.
Fu H; Dou J; Li W; Cui W; Mak S; Hu Q; Luo J; Lam CS; Pang Y; Youdim MB; Han Y
Eur J Pharmacol; 2009 Nov; 623(1-3):14-21. PubMed ID: 19765582
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Abeta production by NF-kappaB inhibitors.
Paris D; Patel N; Quadros A; Linan M; Bakshi P; Ait-Ghezala G; Mullan M
Neurosci Lett; 2007 Mar; 415(1):11-6. PubMed ID: 17223266
[TBL] [Abstract][Full Text] [Related]
13. A novel beta-site amyloid precursor protein cleaving enzyme (BACE) isoform regulated by nonsense-mediated mRNA decay and proteasome-dependent degradation.
Tanahashi H; Tabira T
Neurosci Lett; 2007 Nov; 428(2-3):103-8. PubMed ID: 17961921
[TBL] [Abstract][Full Text] [Related]
14. Age-dependent differential expression of BACE splice variants in brain regions of tg2576 mice.
Zohar O; Pick CG; Cavallaro S; Chapman J; Katzav A; Milman A; Alkon DL
Neurobiol Aging; 2005; 26(8):1167-75. PubMed ID: 15917100
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting β-secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APP.
Boddapati S; Levites Y; Sierks MR
J Mol Biol; 2011 Jan; 405(2):436-47. PubMed ID: 21073877
[TBL] [Abstract][Full Text] [Related]
16. First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates.
Sankaranarayanan S; Holahan MA; Colussi D; Crouthamel MC; Devanarayan V; Ellis J; Espeseth A; Gates AT; Graham SL; Gregro AR; Hazuda D; Hochman JH; Holloway K; Jin L; Kahana J; Lai MT; Lineberger J; McGaughey G; Moore KP; Nantermet P; Pietrak B; Price EA; Rajapakse H; Stauffer S; Steinbeiser MA; Seabrook G; Selnick HG; Shi XP; Stanton MG; Swestock J; Tugusheva K; Tyler KX; Vacca JP; Wong J; Wu G; Xu M; Cook JJ; Simon AJ
J Pharmacol Exp Ther; 2009 Jan; 328(1):131-40. PubMed ID: 18854490
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism.
Vingtdeux V; Hamdane M; Gompel M; Bégard S; Drobecq H; Ghestem A; Grosjean ME; Kostanjevecki V; Grognet P; Vanmechelen E; Buée L; Delacourte A; Sergeant N
Neurobiol Dis; 2005 Nov; 20(2):625-37. PubMed ID: 15936948
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
[TBL] [Abstract][Full Text] [Related]
19. Excess of nicastrin in brain results in heterozygosity having no effect on endogenous APP processing and amyloid peptide levels in vivo.
Brijbassi S; Amtul Z; Newbigging S; Westaway D; St George-Hyslop P; Rozmahel RF
Neurobiol Dis; 2007 Feb; 25(2):291-6. PubMed ID: 17071095
[TBL] [Abstract][Full Text] [Related]
20. Progress toward the discovery and development of efficacious BACE inhibitors.
Durham TB; Shepherd TA
Curr Opin Drug Discov Devel; 2006 Nov; 9(6):776-91. PubMed ID: 17117686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
